Current follow‐up practices often fail to detect metabolic and neurological adverse reactions in children treated with second‐generation antipsychotics
暂无分享,去创建一个
[1] K. Murray,et al. Association of Antipsychotic Treatment With Risk of Unexpected Death Among Children and Youths , 2019, JAMA psychiatry.
[2] K. Lehtimäki,et al. Tardive Dyskinesia Should Not Be Overlooked. , 2019, Journal of child and adolescent psychopharmacology.
[3] J. Iida,et al. Glucose and Prolactin Monitoring in Children and Adolescents Initiating Antipsychotic Therapy , 2018, Journal of child and adolescent psychopharmacology.
[4] J. Newcomer,et al. Metabolic Effects of Antipsychotics on Adiposity and Insulin Sensitivity in Youths: A Randomized Clinical Trial , 2018, JAMA psychiatry.
[5] L. Creel,et al. Psychotropic Polypharmacy Among Children and Youth Receiving Medicaid, 2012-2015 , 2018, Journal of managed care & specialty pharmacy.
[6] A. Sourander,et al. National time trend changes in psychotropic medication of child and adolescent psychiatric inpatients across Finland , 2018, Child and adolescent mental health.
[7] C. Goldie,et al. Patient, Treatment, and Health Care Utilization Variables Associated with Adherence to Metabolic Monitoring Practices in Children and Adolescents Taking Second-Generation Antipsychotics , 2018, Canadian journal of psychiatry. Revue canadienne de psychiatrie.
[8] T. Pringsheim,et al. Antipsychotic Prescribing and Safety Monitoring Practices in Children and Youth: A Population-Based Study in Alberta, Canada , 2018, Clinical Drug Investigation.
[9] H. Akbari,et al. Effect of melatonin in reducing second-generation antipsychotic metabolic effects: A double blind controlled clinical trial. , 2018, Diabetes & metabolic syndrome.
[10] N. Bilenberg,et al. Development of Metabolic Syndrome in Drug-Naive Adolescents After 12 Months of Second-Generation Antipsychotic Treatment. , 2017, Journal of child and adolescent psychopharmacology.
[11] I. Petersen,et al. A multi-national comparison of antipsychotic drug use in children and adolescents, 2005–2012 , 2017, Child and Adolescent Psychiatry and Mental Health.
[12] S. Patten,et al. Feasibility and Relevance of Antipsychotic Safety Monitoring in Children With Tourette Syndrome: A Prospective Longitudinal Study , 2017, Journal of clinical psychopharmacology.
[13] P. de Castro-Manglano,et al. Weight, Height, and Body Mass Index in Patients with Attention-Deficit/Hyperactivity Disorder Treated with Methylphenidate. , 2017, Journal of child and adolescent psychopharmacology.
[14] S. Daniels,et al. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents , 2017, Pediatrics.
[15] Mohammad Reza Mohammadi,et al. Melatonin for Reducing Weight Gain Following Administration of Atypical Antipsychotic Olanzapine for Adolescents with Bipolar Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial. , 2017, Journal of child and adolescent psychopharmacology.
[16] S. Brand,et al. Children with ADHD and symptoms of oppositional defiant disorder improved in behavior when treated with methylphenidate and adjuvant risperidone, though weight gain was also observed – Results from a randomized, double-blind, placebo-controlled clinical trial , 2017, Psychiatry Research.
[17] K. Puura,et al. Clinical use of second-generation antipsychotics in children , 2017 .
[18] Silja Martikainen,et al. Increased Melatonin Signaling Is a Risk Factor for Type 2 Diabetes. , 2016, Cell metabolism.
[19] M. Olfson,et al. Type 2 Diabetes Mellitus in Youth Exposed to Antipsychotics: A Systematic Review and Meta-analysis. , 2016, JAMA psychiatry.
[20] J. Buitelaar,et al. The Safety of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Research , 2015, CNS Drugs.
[21] J. Alda,et al. Neurological Adverse Effects of Antipsychotics in Children and Adolescents , 2015, Journal of clinical psychopharmacology.
[22] C. Correll,et al. Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics. , 2015, Journal of the American Academy of Child and Adolescent Psychiatry.
[23] Sepheen C. Byron,et al. Quality concerns in antipsychotic prescribing for youth: a review of treatment guidelines. , 2014, Academic pediatrics.
[24] S. Frangou,et al. Antipsychotics use in children and adolescents: An on-going challenge in clinical practice , 2014, Journal of psychopharmacology.
[25] S. Owens,et al. Childhood Obesity and the Metabolic Syndrome , 2013, Current Atherosclerosis Reports.
[26] J. Martínez-Ortega,et al. Weight gain and increase of body mass index among children and adolescents treated with antipsychotics: a critical review , 2013, European Child & Adolescent Psychiatry.
[27] J. Rasimas,et al. Adverse Effects and Toxicity of the Atypical Antipsychotics: What is Important for the Pediatric Emergency Medicine Practitioner. , 2012, Clinical pediatric emergency medicine.
[28] C. Panagiotopoulos,et al. Waist Circumference is a Sensitive Screening Tool for Assessment of Metabolic Syndrome Risk in Children Treated with Second-Generation Antipsychotics , 2012, Canadian journal of psychiatry. Revue canadienne de psychiatrie.
[29] L. Dunkel,et al. New Finnish growth references for children and adolescents aged 0 to 20 years: Length/height-for-age, weight-for-length/height, and body mass index-for-age , 2011, Annals of medicine.
[30] W. Dietz,et al. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. , 2003, Archives of pediatrics & adolescent medicine.